Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study

Objective: To determine whether diabetes mellitus (DM) effects progression-free survival (PFS) and overall survival (OS) in women with epithelial ovarian cancer (EOC). Materials and Methods: Tongji Hospital (Wuhan, China) patients presenting with EOC between 2004 and 2012 were included in a retrospective cohort study. Patients were monitored for PFS and OS through October 2014. KaplanMeier and log rank statistical methods were used to compare PFS and OS between diabetes mellitus patients and non-diabetic (ND) patients. Results: A total of 257 patients were included in the study and 64 (24.9%) were diagnosed with diabetes mellitus. Non-diabetic and diabetic mellitus patients were evenly distributed in age, malignant family history, tumor stage, pathology grade, body mass index (BMI), and protein levels of CA125. These results demonstrated that the DM group had worse PFS (31.0 vs. 44.0 months, p = 0.008) and OS (34.0 vs. 55.0 months, p = 0.002) when compared to the ND group. Conclusion: EOC patients with diabetes mellitus have reduced PFS and OS than patients without diabetes.

Diabetes mellitus; Epithelial ovarian cancer; Progression-free survival; Overall survival.

[1] Shaw J.E., Sicree R.A., Zimmet P.Z.: ”Global estimates of the prevalence of diabetes for 2010 and 2030”. Diabetes. Res. Clin. Pract., 2010, 87, 4.

[2] Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., et al.: ”Prevalence of diabetes among men and women in china”. N. Engl. J. Med., 2010, 362, 1090.

[3] Pradeepa R., Mohan V.: ”Prevalence of type 2 diabetes and its complications in India and economic costs to the nation”. Eur. J. Clin. Nutr., 2017, 71, 816.

[4] Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al.: ”Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. Int. J. Cancer., 2015, 136, E359.
[5] Chen W., Zheng R., Baade P.D. Zhang S., Zeng H., Bray F., et al.: ”Cancer statistics in China, 2015”. CA. Cancer. J. Clin., 2016, 66, 115.

[6] Baldwin L.A., Huang B., Miller R.W., Tucker T., Goodrich S.T., Podzielinski I., et al.: ”Ten-year relative survival for epithelial ovarian cancer”. Obstet. Gynecol., 2012, 120, 612.

[7] Ng J.S., Low J.J., Ilancheran A.: ”Epithelial ovarian cancer”. Best. Pract. Res. Clin. Obstet. Gynaecol., 2012, 26, 337.

[8] Deng L., Gui Z., Zhao L., Wang J., Shen L.: ”Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis”. Dig. Dis. Sci., 2012, 57, 1576.

[9] Ben Q., Xu M., Ning X., Liu J., Hong S., Huang W., et al.: ”Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies”. Eur. J. Cancer., 2011, 47, 1928.

[10] MacKenzie T., Zens M.S., Ferrara A., Schned A., Karagas M.R.: ”Diabetes and risk of bladder cancer: evidence from a case-control study in New England”. Cancer., 2011, 117, 1552.

[11] Boyle P., Boniol M., Koechlin A., Robertson C., Valentini F., Coppens K., et al.: ”Diabetes and breast cancer risk: a meta-analysis”. Br. J. Cancer., 2012, 107, 1608.

[12] Chowdhury T.A.: ”Diabetes and cancer”. QJM., 2010, 103, 905.

[13] Kasper J.S., Liu Y., Giovannucci E.: ”Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study”. Int. J. Cancer., 2009, 124, 1398.

[14] Chen H.F., Chang Y.H., Ko M.C., Li C.Y.: ”A large scale population-based cohort study on the risk of ovarian neoplasm in patients with type 2 diabetes mellitus”. Gynecol. Oncol., 2014, 134, 576.

[15] Joung K.H., Jeong J.W., Ku B.J.: ”The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms”. Biomed. Res. Int., 2015, 2015, 920618.

[16] Weiderpass E., Ye W., Vainio H., Kaaks R., Adami H.O.:”Diabetes mellitus and ovarian cancer (Sweden)”. Cancer. Causes. Control., 2002, 13, 759.
[17] Zhou B.F.: ”Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults - Study on optimal cut-off points of body mass index and waist circumference in Chinese adults”. Biomed. Environ. Sci., 2002, 15, 83.

[18] Shah M.M., Erickson B.K., Matin T., McGwin G.Jr., Martin J.Y., Daily L.B., et al.: ”Diabetes mellitus and ovarian cancer: more complex than just increasing risk”. Gynecol. Oncol., 2014, 135, 273.

[19] Stalberg K., Svensson T., Lonn S., Kieler H.: ”The influence of comorbidity on mortality in ovarian cancer patients”. Gynecol. Oncol., 2014, 133, 298.

[20] Quirk J.T. Natarajan N., Mettlin C.J.: ”Age-specific ovarian cancer incidence rate patterns in the United States. Gynecol. Oncol., 2005, 99, 248.

[21] Zhang M., Xie X., Lee A.H., Binns C.W., Holman C.D.: ”Body mass index in relation to ovarian cancer survival”. Cancer. Epidemiol. Biomarkers. Prev., 2005, 14, 1307.

[22] Barrett S.V., Paul J., Hay A., Vasey P.A., Kaye S.B., Glasspool R.M.: ”Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial”. Ann. Oncol., 2008, 19, 898.

[23] Lipscombe L.L., Fischer H.D., Austin P.C., Fu L., Jaakkimainen R.L., Ginsburg O., et al.: ”The association between diabetes and breast cancer stage at diagnosis: a population-based study. Breast. Cancer. Res. Treat., 2015, 150, 613.

[24] Renehan A.G., Yeh H.C., Johnson J.A., Wild S.H., Gale E.A., Møller H.: ”Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer”. Diabetologia., 2012, 55, 1619.

[25] Ding J., Li C., Tang J., Yi C., Liu J.Y., Qiu M.: ”Higher Expression of Proteins in IGF/IR Axes in Colorectal Cancer is Associated with Type 2 Diabetes Mellitus”. Pathol. Oncol. Res., 2016, 22, 773.

[26] Nakae J., Kido Y., Accili D.: ”Distinct and overlapping functions of insulin and IGF-I receptors”. Endocr. Rev., 2001, 22, 818.

[27] Roberts D.L., Dive C., Renehan A.G.: ”Biological Mechanisms Linking Obesity and Cancer Risk: New Perspectives”. Annu. Rev. Med., 2010, 61, 301.

[28] Hua K., Feng W., Cao Q., Zhou X., Lu X., Feng Y.: ”Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer”. Int. J. Oncol., 2008, 33, 959.

[29] Donath M.Y., Shoelson S.E.: ”Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol., 2011, 11, 98.

[30] Spranger J., Kroke A., Möhlig M., Hoffmann K., Bergmann M.M., Ristow M., et al.: ”Inflammatory cytokines and the risk to develop type 2 diabetes - Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)- Potsdam study”. Diabetes., 2003, 52, 812.

[31] Liu Y., Wu Y., Wang Y., Zhang M., Li Z.: ”Increased Levels of Serum Protein Complexes Are Associated with Type 2 Diabetes”. Int. J. Med. Sci., 2018, 15, 210.

[32] Lane D., Matte I., Rancourt C., Piche A.: ”Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients”. BMC. Cancer., 2011, 11, 210.

[33] Alberti K., Zimmet P.Z.: ”Definition, diagnosis and classification of diabetes mellitus and its complications part 1: Diagnosis and classification of diabetes mellitus - Provisional report of a WHO consultation”. Diabet. Med., 1998, 15, 539.

[34] Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A.: ”Global cancer statistics, 2012”. CA Cancer J Clin., 2015, 65, 87.